ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Factors influencing the use of hypofractionated radiotherapy in prostate cancer: a nationwide survey of radiation oncologists in Turkiye (TROD 09-008).
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate contemporary practice patterns in prostate cancer radiotherapy (RT) in Turkiye, with a particular focus on the adoption of hypofractionated and ultrahypofractionated regimens, and to identify factors influencing fractionation preferences among radiation oncologists specialized in uro-oncology.
methodsA cross-sectional, web-based survey consisting of 14 items was distributed to registered members of the Turkish Society for Radiation Oncology (TROD) Uro-Oncology Working Group between September and December 2024. The questionnaire assessed physician demographics, institutional characteristics, technological infrastructure, prostate cancer patient volume, preferred RT fractionation across predefined clinical scenarios, and perceived rationales and barriers to hypofractionation. Descriptive statistics were used to summarize responses, and multivariable logistic regression analysis was performed to identify factors independently associated with hypofractionation use. Analyses were performed using SPSS version 23.0 (IBM Corp., Armonk, NY).
resultsThe survey achieved a response rate of 42.9% (n = 54). Most respondents had ≥ 11 years of clinical experience (96.2%), and 43.7% were employed in private institutions. Advanced RT technologies were widely available, including intensity-modulated radiotherapy (IMRT) (92.6%), volumetric modulated arc therapy (VMAT) (85.2%), stereotactic body radiotherapy (SBRT)-capable platforms (88.9%), and cone-beam computed tomography (CBCT)-based image guidance (85.2%). Hypofractionation was most frequently preferred in low- and intermediate-risk prostate cancer, whereas conventional fractionation predominated in high-risk disease, pelvic irradiation, and adjuvant or salvage settings. In palliative scenarios, hypofractionation was overwhelmingly favored. On multivariable analysis, treating more than 11 new prostate cancer patients per month was independently associated with increased use of hypofractionated RT (p = 0.04).
conclusionsDespite high technological readiness and increasing adoption of hypofractionation among specialized uro-oncology practitioners, Turkish radiation oncologists exhibit caution in high-risk and postoperative settings. Higher clinical volume significantly drives the transition to shorter regimens, suggesting that clinical experience is a key catalyst for closing the evidence-practice gap.
Indexed as
Identifiers
42171982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.